Sclerostin Antibodies (Romosozumab)
Overview
Romosozumab is a humanized monoclonal antibody that binds and inhibits sclerostin, a glycoprotein produced by osteocytes that negatively regulates the Wnt signaling pathway. By blocking sclerostin, romosozumab increases Wnt pathway activity in osteoblasts, simultaneously promoting bone formation and reducing bone resorption. This dual mechanism produces rapid and substantial increases in bone mineral density. The antibody is composed of two heavy and two light immunoglobulin chains in a standard IgG2 configuration.
Key Research Findings
Romosozumab received FDA approval in 2019 based on the FRAME and ARCH trials, which demonstrated significant reductions in vertebral, clinical, and hip fractures in postmenopausal women with osteoporosis. The ARCH trial (NEJM, 2017) showed superior fracture reduction compared to alendronate over 24 months. A boxed warning was added regarding cardiovascular risk, including myocardial infarction and stroke, based on numerical imbalances observed in the ARCH study.
Subcutaneous injection
FDA Approved
Interested in Sclerostin Antibodies (Romosozumab)?
Find a verified provider experienced with Sclerostin Antibodies (Romosozumab) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Sclerostin Antibodies (Romosozumab) ProviderRelated Peptides
Teriparatide (Forteo)
FDA ApprovedA recombinant form of the first 34 amino acids of human parathyroid hormone (PTH 1-34). When administered intermittently via daily subcutaneous injection, teriparatide stimulates osteoblastic bone formation more than osteoclastic resorption, producing a net anabolic effect on bone. It activates the PTH1 receptor on osteoblasts, increasing Wnt signaling, osteoblast differentiation, and survival while reducing sclerostin expression.
Abaloparatide (Tymlos)
FDA ApprovedA synthetic 34-amino acid peptide analog of parathyroid hormone-related protein (PTHrP 1-34) that selectively activates the RG conformation of the PTH1 receptor. This receptor selectivity produces a more transient signaling response compared to teriparatide, favoring anabolic bone formation with less stimulation of bone resorption and calcium mobilization. Abaloparatide increases bone mineral density at both cortical and trabecular sites.
Calcitonin
FDA ApprovedA 32-amino acid peptide hormone naturally produced by parafollicular C-cells of the thyroid gland. Calcitonin inhibits osteoclast-mediated bone resorption by binding to calcitonin receptors on osteoclasts, reducing their activity and number. Salmon calcitonin is approximately 40-50 times more potent than human calcitonin and has a longer half-life, making it the preferred therapeutic form.
Vosoritide (Voxzogo)
FDA ApprovedA C-type natriuretic peptide (CNP) analog that acts as an agonist at the natriuretic peptide receptor B (NPR-B) on growth plate chondrocytes. Vosoritide counteracts the constitutively activated FGFR3 signaling that suppresses endochondral ossification in achondroplasia. By stimulating the NPR-B/cGMP/MAPK pathway, it antagonizes the growth-inhibitory FGFR3 signal and restores more normal linear bone growth.